புதுமையானது சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புதுமையானது சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புதுமையானது சிகிச்சை Today - Breaking & Trending Today

OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma


Posted April 15th, 2021 for OncoSec Medical
April 15, 2021 8:30am EDT
PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 / /  OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA
® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10
th World Congress of Melanoma. This is an encore presentation of data presented at The Society for Immunotherapy of Cancer s (SITC) 2020 Annual Meeting. Presenters will also discuss the therapeutic potential of OncoSec s DNA medicines platform to elicit robust anti-tumor immunity via intratumoral gene electrotransfer of TAV ....

Christopherg Twitty , Paolo Ascierto , Paoloa Ascierto , Oncosec Medical Incorporated , National Tumor Institute Fondazioneg Pascale , Society For Immunotherapy Of Cancer , Company Or Oncosec , Drug Administration , Food Drug Administration , World Congress , Innovative Therapy , National Tumor Institute Fondazione , Fast Track Designation , Orphan Drug , சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் , உலகம் காங்கிரஸ் , புதுமையானது சிகிச்சை , வேகமாக டிராக் பதவி , ஆர்ஃபந் மருந்து ,

Open Book Extracts and Case Western Reserve University School of Medicine Announce Research Agreement for Novel Rare Cannabinoid Therapeutics


Open Book Extracts and Case Western Reserve University School of Medicine Announce Research Agreement for Novel Rare Cannabinoid Therapeutics
Open Book Extracts and Case Western Reserve University School of Medicine announce research agreement to explore the mechanistic effects of rare cannabinoids on brain cell functions, including CBD, CBG, CBN, CBC, THVC, and CBDV.
News provided by
Share this article
Share this article
ROXBORO, N.C., Jan. 12, 2021 /PRNewswire/  Open Book Extracts (OBX), manufacturer and distributor of the industry s most innovative and highest quality cannabinoid ingredients and finished products, and Case Western Reserve University School of Medicine, one of the country s leading private research institutions, announced today they have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions. ....

United States , Hong Kong , North Carolina , Ruth Weber Goodman , Nicole Brown , Paul Tesar , Dave Neundorfer , Case Western Reserve School Of Medicine , Louis Stokes Va Medical Center , Health Education Campus , School Of Medicine , Case Western Reserve University School Of Medicine , Carolina Research Triangle , Genome Sciences , Department Of Genetics , Open Book Extracts , Case Western Reserve University School , Case Western Reserve , Ruth Weber Goodman Professor , Innovative Therapeutics , Case Western Reserve School , Convelo Therapeutics , Western Reserve , Case Western , Chief Revenue Officer , Research Triangle ,